Endothelial cell-specific molecule-1/endocan

• Verfasst von: Pauly, Dominic [VerfasserIn]
• Verfasst von: Hamed, Sonja [VerfasserIn]
• Verfasst von: Behnes, Michael [VerfasserIn]
• Verfasst von: Lepiorz, Dominic [VerfasserIn]
• Verfasst von: Lang, Siegfried [VerfasserIn]
• Verfasst von: Akın, Ibrahim [VerfasserIn]
• Verfasst von: Borggrefe, Martin [VerfasserIn]
• Verfasst von: Hoffmann, Ursula [VerfasserIn]
• Titel: Endothelial cell-specific molecule-1/endocan
• Titelzusatz: diagnostic and prognostic value in patients suffering from severe sepsis and septic shock
• Verf.angabe: Dominic Pauly, MS, Sonja Hamed, MS, Michael Behnes, MD, Dominic Lepiorz, MS, Siegfried Lang, PhD, Ibrahim Akin, MD, Martin Borggrefe, MD, Thomas Bertsch, MD, Ursula Hoffmann, MD
• E-Jahr: 2016
• Jahr: February 2016
• Umfang: 8 S.
• Fussnoten: Gesehen am 04.02.2019
• Titel Quelle: Enthalten in: Journal of critical care
• Ort Quelle: [Amsterdam] : Elsevier, 1986
• Jahr Quelle: 2016
• Band/Heft Quelle: 31(2016), 1, Seite 68-75
• ISSN Quelle: 1557-8615
• DOI: doi:10.1016/j.jcrc.2015.09.019
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Prognosis
• Sach-SW: Diagnosis
• Sach-SW: Endocan
• Sach-SW: Intensive care unit
• Sach-SW: Septic shock
• Sach-SW: Severe sepsis
• K10plus-PPN: 1587254425

Abstract

Purpose: This study aims to assess the diagnostic and prognostic value of endocan in patients with severe sepsis or septic shock on a medical intensive care unit (ICU). Methods: 150 patients suspected for at least severe sepsis were enrolled on a medical ICU. On days 1, 3, and 8, plasma levels of endocan, procalcitonin (PCT), and interleukin (IL)-6 were measured. Follow-up on all-cause mortality was performed after 30 days and 6 months. Results: Endocan correlated with Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA), and Simplified Acute Physiology Score II (SAPS II) (P < .006). Endocan was higher in patients with at least severe sepsis compared with systemic inflammatory response syndrome (SIRS) or sepsis patients (P = .0006) on days 1, 3, and 8. With a minimum sensitivity of 70%, uniform cutoff levels were set for ≥ sepsis at 1.8 ng/mL, for ≥ severe sepsis at 2.6 ng/mL, for ≥ septic shock at 2.9 ng/mL. On day 1, endocan levels of the fourth quartile were significantly associated with 30-days and 6-months mortality compared to lower levels. After adjustment in Cox regressions, endocan still revealed prognostic value. Conclusions: Endocan showed diagnostic capacity to diagnose patients with severe sepsis and septic shock and revealed prognostic information for 30-days and 6-months all-cause mortality.